Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (Sac-TMT) at 2024 CSCO Congress
Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (Sac-TMT) at 2024 CSCO Congress
2024年CSCO大會上，科倫生物的TROP2-ADC SKB264（Sac-TMT）的多個研究結果
CHENGDU, China, Sept. 28, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held in Xiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront of clinical practice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) presented multiple clinical research results and progress of TROP2 ADC sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) at the conference.
2024年9月25日至29日，第27屆中國臨床腫瘤學大會暨2024年CSCO年會在廈門舉行。來自中國各地的腫瘤學專家學者齊聚一堂，討論臨床實踐前沿的熱點問題。四川科倫-生物科藥有限公司（"科倫-生物科"，6990.HK）在會議上展示了TROP2 ADC亞單抗耐替單抗（sac-TMt，原SKB264/Mk-2870）的多項臨床研究成果和進展。
TNBC
TNBC
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。